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Background: Hypoglycemic episodes are infrequent in individuals without a history of diabetes mellitus or bariatric
surgery. When hypoglycemia does occur in such individuals, an uncommon but important diagnosis to consider is
non-islet cell tumor hypoglycemia (NICTH). We report a case of NICTH associated with paraneoplastic insulin-like
growth factor-2 (IGF-2) production and review current relevant medical literature.
Case presentation: A 60 year old male with no relevant past medical history was referred to the endocrinology
clinic with 18 month history of episodic hypoglycemic symptoms and, on one occasion was noted to have a
fingerstick glucose of 36 mg/dL while having symptoms of hypoglycemia. Basic laboratory evaluation was
unrevealing. Further evaluation however showed an elevated serum IGF-2 level at 2215 ng/mL (reference range
411–1248 ng/mL). Imaging demonstrated a large right suprarenal mass. A right nephrectomy with resection of the
mass demonstrated a malignant solitary fibrous tumor. Post resection, the patient’s IGF-2 levels normalized and
hypoglycemic symptoms resolved.
Conclusion: Due to the structural and biochemical homology between IGF-2 and insulin, elevated levels of IGF-2
can result in hypoglycemia. A posttranslational precursor to IGF-2 known as “big IGF” also possesses biologic activity.
Review of recent reported cases of NICTH identified widespread anatomic locations and varied pathologic diagnoses of
tumors associated with paraneoplastic production of IGF-2 causing hypoglycemia. Definitive management of
hypoglycemia associated with paraneoplastic production of IGF-2 consists of resection of the tumor responsible
for IGF-2 production. Accumulating literature provides a firm basis for routine IGF-2 laboratory evaluation in
patients presenting with spontaneous hypoglycemia with no readily apparent cause.
Keywords: Non islet cell tumor hypoglycemia (NICTH), Insulin like Growth Factor–2 (IGF-2), Big IGF-2,
Hypoglycemia, Paraneoplastic production, Insulinoma, Solitary fibrous tumorBackground
Hypoglycemia is a common medical problem in patients
with diabetes mellitus treated with insulin or insulin se-
cretagogues. Hypoglycemia is also associated with gastric
bypass weight loss surgery [1].
Although rare, hypoglycemia is occasionally encoun-
tered in non-diabetic, non-gastric bypass patients. In* Correspondence: khowa002@umn.edu
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unless otherwise stated.such patients, hypoglycemia is usually a manifestation
of pancreatic islet cell tumors producing insulin, pri-
mary or secondary adrenal insufficiency, advanced liver
disease, pheochromocytoma, IGF-1 secreting tumors,
hypothyroidism, substances interfering with insulin and
insulin receptor mediated metabolism [non-islet cell
tumor hypoglycemia (NICTH)] or antibodies interfering
with insulin receptors [2].
In subjects with recurrent hypoglycemia and no history
of diabetes or weight loss surgery, NICTH is an important
disorder to consider in the differential diagnosis. Tumorsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Laboratory evaluation of current case
Test Results Reference range
Insulin (after overnight fast) < 2 mU/L 0 – 20 mU/L
C-Peptide (after overnight fast) < 0.1 ng/mL 0.9 – 6.9 ng/mL
Plasma glucose (after overnight
fast)
35 mg/dL 60 – 99 mg/dL
ALT 19 U/L 0 – 70 U/L
AST 27 U/L 0 – 55 U/L
Alkaline Phosphatase 75 U/L 40 – 150 U/L
Total Bilirubin Undetectable 0.0 – 0.3 mg/dL
Albumin 4.4 g/dL 3.3 – 4.9 g/dL
Total Protein 5.2 g/dL 6.8 – 8.8 g/dL
Hemoglobin A1c 4.9% 4.0 – 6.0%
α–Fetoprotein 5.5 ug/L 0 – 8 ug/L
IGF-I < 0.1 ug/L 0 – 5 ug/L
TSH 1.45 mU/L 0.4 – 5.0 mU/L
Free T4 0.98 ng/dL 0.70 – 1.85 ng/dL
Plasma Norepinephrine 549 pg/mL 80 – 520 pg/mL
Plasma free Normetanephrine 0.65 mmol/L < 0.9 mmol/L
Plasma Epinephrine 117 pg/mL 10 – 200 pg/mL
Plasma free Metanephrine 0.23 mmol/L < 0.5 mmol/L
Cortisol 11 ug/dL 4 – 22 ug/dL
Adrenocorticophic Hormone 23 pg/mL < 47 pg/mL
IGF-2 (at diagnosis) 2215 ng/mL 414 – 1248 ng/mL
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nancies associated with insulin receptor antibodies, tumor
necrosis factor (TNF), interleukin (IL) -1 or −6; pheochro-
mocytoma associated with excess catecholamine produc-
tion; and paraneoplastic production of IGF-1 or IGF-2 [2].
In this article, we report a case of NICTH associated
with paraneoplastic IGF-2 production. We have also
reviewed the current literature on the subject and de-
scribe pathophysiology, diagnostic methods and treat-
ment options.
Case presentation
A 60 year old male was referred to the Endocrinology
clinic at the University of Minnesota for the evaluation
of worsening symptoms that included diaphoresis, anxiety,
inability to concentrate and episodic visual changes for the
prior 18 months. Patient reported waking from sleep dur-
ing the night with symptoms. He had discovered that
carbohydrate rich snacks every 30 – 60 min prevented his
symptoms. As a result of frequent snacking on carbohy-
drate containing foods, he had gained 30 pounds in the
prior 12 months. He did not experience symptoms post-
prandially. During one of his episodes, he obtained a
finger stick glucose value of 36 mg/dL. His past medical
history included hypertension, dyslipidemia and ob-
structive sleep apnea. He did not have history of dia-
betes mellitus or bariatric surgery. His medications
included metoprolol extended release, hydrochlorothia-
zide, irbesartan, amlodipine, aspirin, terazosin, simvastatin
and omeprazole. He occasionally consumed alcohol and
had a remote history of smoking. Physical examination
was within normal limits except for body mass index
(BMI) of 33.2 kg/m2.
Serial finger stick blood glucose monitoring during symp-
tomatic episodes demonstrated recurrent hypoglycemia
with blood glucose values of 41, 35 and 41 mg/dL. Diagno-
ses considered included medication induced hypoglycemia,
insulinoma, chronic liver disease, pheochromocytoma
and adrenal insufficiency. These diagnoses were excluded
based on laboratory evaluation (Table 1).
Subsequently, IGF-2 was measured and found to be
2215 ng/mL (reference range: 414 – 1248 ng/mL). Com-
puted Tomography (CT) without contrast of chest, abdo-
men and pelvis showed a large right suprarenal mass
measuring 14 × 17 × 16 cm, which was lobular in shape
with central necrosis and calcifications (Figure 1). Techne-
tium radionuclide bone scan did not show any metastatic
disease.
The patient underwent right nephrectomy and resec-
tion of the mass. Surgical pathology showed a malignant
solitary fibrous tumor with spindled to epithelioid cells
and focal high-grade nuclear atypia (Figure 2). The
tumor cell proliferation marker Ki67 index was elevated.
The tumor was positive for CD34, CD99 and Bcl-2consistent with a diagnosis of malignant solitary fibrous
tumor.
The patient’s follow-up IGF-2 levels were within the
normal range (Table 2). He did not experience further
episodes of hypoglycemia and was able to lose 10 lbs
over the next six months. A three year follow-up CT
scan of the abdomen did not demonstrate any evidence
of recurrence.Discussion
The IGF-2 gene is located on short arm of chromosome
11 (11p15) adjacent to the insulin (INS) gene [3]. IGF-2
is a 67 amino acid polypeptide with 47% sequence hom-
ology with insulin. Post translational prepro IGF-2 con-
tains 180 amino acids with a carboxy terminal peptide of
89 amino acids and a signal peptide of 24 amino acids.
Prepro IGF-2 is cleaved to form mature IGF-2 [4]. Pre-
pro IGF-2 molecules (known as “big IGF-2”) have also
been shown to have biologic activity and can produce
hypoglycemia in the setting of a normal IGF-2 level [5].
It is due to the structural and biochemical homology be-
tween IGF-2 and insulin that an unregulated and elevated
level of IGF-2 stimulates glucose metabolism pathways
thus leading to hypoglycemia [6].
Figure 1 Non contrast Computed Tomography (CT) of chest, abdomen and pelvis; transverse and coronal views.
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by the liver. However, other tissues may also produce IGF-
2, allowing it to exert effects through endocrine, autocrine
and paracrine pathways [7]. Physiologically, IGF-2 plays
an important role in human fetal and post-natal develop-
ment but whether it has significant physiological function
in adults remain unknown [8]. As opposed to IGF-1, IGF-
2 regulation is independent of growth hormone [9]. IGF-1
and IGF-2 both have glucose lowering potency that is
approximately 5% of insulin’s potency. However, plasma
concentrations of IGF-1 and IGF-2 can be 1000 times
greater than insulin in NICTH allowing them to cause
hypoglycemia [10]. More than 95% of IGF-2 in the cir-
culation is bound to insulin like growth factor binding
proteins (IGFBP) that have high affinity for both IGF-1
and IGF-2 [11]. In spite of structural homology with insu-
lin, normal levels of IGF-2 do not cause hypoglycemia. At
the cellular level, IGF-2 binds with IGF2R which is re-
sponsible for endocytosis, intracellular hormone transport
and degradation of circulating IGF-2 [12].Figure 2 Hematoxylin and Eosin (H&E) staining of surgically
resected tumor. Magnification 40x.Tumors producing elevated levels of circulating IGF-2
with resulting hypoglycemia are categorized as NICTH.
NICTH has also been reported in conjunction with
paraneoplastic production of insulin receptor antibodies,
tumor necrosis factor (TNF), interleukin (IL) -1 and −6,
catecholamine (pheochromocytoma) and IGF-1 [2]. For
reasons not clear, there are several neoplasms noted to
have high levels of IGF-2 mRNA without exhibiting
elevated hormone activity [13].
The IGF-2 gene is an imprinted gene; normally only one
parental allele is expressed [14]. Loss of imprinting leads
to over expression of IGF-2 and has been demonstrated
in multiple tumors including solitary fibrous tumors
(independent of anatomical location), Wilm’s tumors,
metastatic hemangiopericytomas, mesotheliomas, hepa-
tocellular carcinomas, gastrointestinal stromal tumors
(GIST), colorectal adenomas, osteosarcomas, rhabdo-
myosarcomas, leiomyosarcomas, paragangliomas, pros-
tate cancers, breast cancers and bladder cancers [2,15].
Although these neoplasms often have elevated levels of
IGF-2 mRNA, they do not always produce elevated cir-
culating levels of IGF-2 or big IGF-2. Genetic and epigen-
etic mechanisms that determine isolated transcription of
mRNA and the production of IGF-2 and big IGF-2 are not
well understood; however, these mechanisms are thought
to play an important role in carcinogenesis and tumor
growth [13,16].
In a previous extensive review of this topic by de
Groot and coauthors in 2007, authors noted that 41% ofTable 2 Post-operative serial hormone concentration
Time post tumor
resection (months)
Serum IGF-2 level Serum IGF-1 level
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of mesenchymal origin, 43% of epithelial origin, 1% of
neuroendocrine and hematopoietic origin and 14% of un-
known origin [2]. Although symptoms of hypoglycemia
were predominant, other symptoms included skin tags,
acne and rhinophyma.
We reviewed case reports of NICTH associated with
paraneoplastic production of IGF-2 from 2008 to 2012
(Table 3) [17-38]. On our review of literature, we identi-
fied 22 published reports of NICTH with elevated IGF-2Table 3 Cases of hypoglycemia from NICTH secreting IGF-2 re
Reference Age/sex Tumor site Tum
[17] 28, male Retroperitoneal pelvic region Mali
tum
[18] 68, male Liver Solit
[19] 59, male Lungs and bones Men
hem
[20] 75, male Left pleural cavity Pleu
tum
[21] 65, male Retroperitoneal tumor Retr
fibro
[22] 66, female Right inferior thorax Solit
[23] 53, male Liver Met
hem
[24] 64, female Right lower thorax Mali
tum
[25] 83, male Retroperitoneum Mali
tum
[26] 43, male Right posterior cranial fossa, metastatic lesions
in bilateral kidney, right iliopsoas muscle, right
iliac body, thoracic vertebra 10 body and
segment IV of the liver
Men
hem
[27] 59, female Right hemithorax Solit
[28] 67, male Pelvis Solit
[29] 49, female Right breast Ben
[30] 49, female Left breast High
sarc
[31] 80, female Uterus Uter
[32] 69, male Spleen, lungs, liver Hep
[33] 61, male Liver Poo
gast
[34] 27, female Lung and liver Ova
[35] 53, female Right adrenal gland, liver
[36] 45, Male Pelvis and peritoneum Des
roun
[37] 77, male Liver and lungs Hep
[38] 41, male Pleura and posterior mediastinum Solitlevels causing hypoglycemia. Age range of the patients
was 27 – 83 years (mean age 58 years), with 14 males
and 8 females. Predominant symptoms included those of
hypoglycemia (diaphoresis, tremor, anxiety, loss of con-
sciousness) and mechanical symptoms depending on site
of the tumor. Some tumors were associated with acromeg-
aly. The anatomic location of tumors in these case reports
included liver (n = 9), pleural cavities (n = 5), lungs (n = 3),
retroperitoneum (n = 3), bones (n = 2), pelvis (n = 2),
breasts (n = 2), cranium (n = 1), kidney (n = 1), uterusported from 2008 till 2012
or pathology Hormone elevated Management
gnant solitary fibrous
or
IGF-2 Surgical resection of
turmor








Big IGF-2 Surgical resection
operitoneal solitary
us tumor
IGF-2, Big IGF-2 Surgical resection


















ary fibrous tumor Elevated IGF-2/IGF-1
ratio
Surgical resection








ine leiomyoma IGF-II, elevated IGF-
2/IGF-1 ratio
Exploratory laparotomy


















atocellular carcinoma Big IGF-2 chemotherapy
ary fibrous tumor Big IGF-2 chemotherapy
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tumor involved more than one organ system in 6 pa-
tients. Fifteen patients were diagnosed with NICTH for
the first time, whereas 7 patients presented with recurrent
disease. Pathologic diagnosis included solitary fibrous
tumor (n = 10), hemangiopericytoma (n = 3), phyllodes
tumor and sarcoma (n = 2), hepatocellular carcinoma
(n = 2), uterine leiomyoma (n = 1), gastric adenocarcin-
oma (n = 1), ovarian germ cell tumor (n = 1), pheochromo-
cytoma (n = 1) and desmoplastic small round cell tumor
(n = 1). Hypoglycemia associated with IGF-2 production
has also been reported in pancreatic islet cell tumor [39].
Biochemical profiles of the patients varied and included
elevated IGF-2, elevated big IGF-2 with normal IGF-2,
and elevated IGF-2 to IGF-1 ratio.
Currently, different assays are being used in clinical
and research settings for measurement of IGF-2. These
assays utilize liquid chromatography–mass spectrometry
(LC-MS) [40] or immunoassay (ELISA and RIA). West-
ern blot is used for measurement big IGF-2 [41]. The
possibility of NICTH secondary to IGF-2 is suggested
by low blood glucose along with suppressed insulin, C-
peptide and IGF-1 levels. Concurrent normal to high
morning cortisol and normal response on cosyntropin
stimulation can rule out adrenal insufficiency and sug-
gest NICTH secondary to IGF-2. IGF-2 levels are fre-
quently within the normal range in NICTH, and assays
for big IGF-2 are not commercially available. Thus, the
IGF-2: IGF-1 ratio is used as a surrogate marker for big
IGF-2 concentration. A ratio of >10 is considered to be
clinically significant [42].
Management of NICTH can be divided into issues re-
lated to 1) hypoglycemia and 2) the underlying tumor.
Hypoglycemia can be managed in a typical manner by
administration of oral glucose, intravenous dextrose or
glucagon depending upon the severity. Glucocorticoid
therapy has been shown to suppress big IGF-2 in a dose
dependent manner using doses of 30–60 mg/d of pred-
nisolone or 4 mg/d of dexamethasone [43]. Surgical re-
section of the tumor, whenever possible, is the treatment
of choice and, if successful, usually results in the reso-
lution of hypoglycemia and other metabolic abnormal-
ities. In cases where complete resection is not feasible
due to tumor infiltration and/or distant metastasis, sur-
gical debulking along with chemoradiation can be con-
sidered for treatment of hypoglycemia. The choice of
chemotherapy depends upon the primary pathology of
the tumor. Metastatic disease and tumor recurrence are
associated with a poor prognosis.
Conclusion
NICTH is a rare cause of hypoglycemia in the general
population. It is associated with elevated levels of IGF-2,
high molecular weight IGF-2 (big-IGF-2) or an increasedIGF-2 to IGF-1 ratio. Diagnosis of paraneoplastic IGF-2
induced hypoglycemia is an important and time sensitive
consideration since earlier detection of tumors provides
a better opportunity for complete resection and subsequent
resolution of hypoglycemia. Whether IGF-2 level should be
routinely measured in the evaluation of hypoglycemia de-
pends on the prevalence of the condition. Accumulating
literature supports screening for IGF-2 in non-diabetic
individuals who present with hypoglycemia along with
suppressed insulin and c-peptide levels.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying im-
ages. A copy of the written consent is available for review.
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